Non-24-hour sleep-wake syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Oct 2010Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

Vanda Pharmaceuticals — PHASE3

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

HETLIOZ

Vanda Pharmaceuticals, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

HETLIOZ

(tasimelteon)Orphan drugstandard

Vanda Pharmaceuticals, Inc.

Melatonin Receptor Agonist [EPC]

12.1 Mechanism of Action The mechanism by which tasimelteon exerts its therapeutic effect in patients with Non-24 or nighttime sleep disturbances in S...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial
1Phase 3
1Total recruiting
Search clinical trials for Non-24-hour sleep-wake syndrome

Recent News & Research

No recent news articles indexed yet for Non-24-hour sleep-wake syndrome.
Search PubMed for Non-24-hour sleep-wake syndrome

Browse all Non-24-hour sleep-wake syndrome news →

Specialist Network

No specialists currently listed for Non-24-hour sleep-wake syndrome.

View all Non-24-hour sleep-wake syndrome specialists →

Quick Actions